1
=
-
KONINKLIJKE PHILIPS N.V.
As of May 18, 2026 at 24:05 UTC
Chart
About KONINKLIJKE PHILIPS N.V.
Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. Nearly 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, and image-guided therapy solutions. The connected care segment (under 30% of revenue) encompasses monitoring and analytics systems for hospitals, informatics business, and also houses the sleep and respiratory care segment. Personal health business (remainder of revenue) is mainly oral health and personal care product lines, which include electric toothbrushes and men's grooming and personal-care products.
Market Statistics
Trading Metrics
How to Buy PHG
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy PHG
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesThe global computer vision in healthcare market is projected to grow from $4.37 billion in 2026 to $33.4 billion by 2036, at a CAGR of 22.6%. Growth is driven by AI-integrated diagnostic systems, radiologist shortages, and precision medicine adoption. Software and medical imaging segments lead the market, while Asia-Pacific is expected to see the fastest regional growth.
The global healthcare analytics market is projected to grow from USD 56 billion in 2025 to USD 390 billion by 2034, with a CAGR of ~24%. Growth is driven by widespread EHR adoption, rising chronic disease prevalence, shift toward value-based care, AI/ML integration, and government digital health initiatives. North America leads with 44.36% market share, while Asia-Pacific emerges as a major growth engine.
Koninklijke Philips reported strong Q1 2026 results with 6% order intake growth and 4% comparable sales increase, beating earnings expectations at 27 cents per share versus 23 cents consensus. However, sales of $4.57 billion slightly missed the $4.60 billion consensus. The company maintained its 2026 outlook for 3%-4.5% comparable sales growth and 12.5%-13.0% adjusted EBITA margin. Stock was up 2.72% at $27.17 despite technical indicators showing fading momentum.
The global sleep apnea devices market is expected to grow at a CAGR of 7.05% from 2025 to 2034, driven by rising prevalence of sleep apnea affecting approximately 1 billion people worldwide, increased obesity rates, and technological innovations in CPAP, BiPAP, and oral appliances. Growth is further supported by expanding homecare and telemedicine adoption. However, challenges include high device costs, limited access in developing regions, and poor patient compliance with therapy.
Royal Philips announced the launch of Bridge Plus Occlusion Balloon, a next-generation device designed to rapidly control bleeding during rare superior vena cava (SVC) tears in transvenous lead extraction procedures. The device can deploy in under two minutes, stop up to 90% blood loss, and maintain hemostasis for 30 minutes. Clinical evidence shows survival rates improved from 56.9% to 88.2% when an occlusion balloon was staged in advance. The product is now commercially available in the United States with international availability expected later in 2026.